{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:13:33Z","timestamp":1767849213519,"version":"3.49.0"},"reference-count":17,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,2,6]],"date-time":"2017-02-06T00:00:00Z","timestamp":1486339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cutan Pathol"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>5\u2010Hydroxymethylcytosine (5\u2010<jats:styled-content style=\"fixed-case\">hmC<\/jats:styled-content>) is an epigenetic marker detectable through immunohistochemistry (<jats:styled-content style=\"fixed-case\">IHC<\/jats:styled-content>) that has been shown to distinguish benign nevi from melanoma with high sensitivity and specificity. The purpose of the study was to explore its diagnostic utility in a subset of histologically challenging, heavily pigmented cutaneous melanocytic neoplasms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>5\u2010<jats:styled-content style=\"fixed-case\">hmC IHC<\/jats:styled-content> was performed on 54 heavily pigmented melanocytic tumors. Semi\u2010quantitative analysis of immunoreactivity was correlated with clinical, pathologic and follow\u2010up data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Benign melanocytic neoplasms (4 of 4 blue nevi with epithelioid change; 12 of 12 combined nevi; 5 of 5 deep penetrating nevi, <jats:styled-content style=\"fixed-case\">DPN<\/jats:styled-content>) exhibited strong 5\u2010<jats:styled-content style=\"fixed-case\">hmC<\/jats:styled-content> nuclear reactivity. Eight heavily pigmented blue nevus\u2010like melanomas and 7 of 8 pigmented epithelioid melanocytomas (<jats:styled-content style=\"fixed-case\">PEM<\/jats:styled-content>) showed significant 5\u2010<jats:styled-content style=\"fixed-case\">hmC<\/jats:styled-content> loss. Five of 7 atypical <jats:styled-content style=\"fixed-case\">DPN<\/jats:styled-content> cases and 8 of 10 melanocytic tumors of uncertain malignant potential (<jats:styled-content style=\"fixed-case\">MELTUMP<\/jats:styled-content>) showed low to intermediate 5\u2010<jats:styled-content style=\"fixed-case\">hmC<\/jats:styled-content> immunoreactivity. These differences were statistically significant (<jats:italic>P<\/jats:italic>\u2010value &lt;.0001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Loss of 5\u2010<jats:styled-content style=\"fixed-case\">hmC<\/jats:styled-content> may be helpful in differentiating benign, diagnostically challenging, heavily pigmented melanocytic tumors from those with malignant potential. The intermediate to low 5\u2010<jats:styled-content style=\"fixed-case\">hmC<\/jats:styled-content> immunoreactivity in atypical <jats:styled-content style=\"fixed-case\">DPNs<\/jats:styled-content>, <jats:styled-content style=\"fixed-case\">PEMs<\/jats:styled-content> and so\u2010called <jats:styled-content style=\"fixed-case\">MELTUMP<\/jats:styled-content> categories further underscores the need to consider these neoplasms as having some potential for lethal biological behavior.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cup.12880","type":"journal-article","created":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T10:14:53Z","timestamp":1483006493000},"page":"249-255","source":"Crossref","is-referenced-by-count":19,"title":["5\u2010Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms"],"prefix":"10.1111","volume":"44","author":[{"given":"Jonathan J.","family":"Lee","sequence":"first","affiliation":[{"name":"Program in Dermatopathology Brigham and Women's Hospital, Harvard Medical School  Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo E.","family":"Vilain","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia  North Sydney Australia"},{"name":"Sydney Medical School The University of Sydney  Sydney NSW Australia"},{"name":"Tissue Pathology and Diagnostic Oncology Royal Prince Alfred Hospital  Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott R.","family":"Granter","sequence":"additional","affiliation":[{"name":"Program in Dermatopathology Brigham and Women's Hospital, Harvard Medical School  Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina R.","family":"Hu","sequence":"additional","affiliation":[{"name":"Program in Dermatopathology Brigham and Women's Hospital, Harvard Medical School  Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott C.","family":"Bresler","sequence":"additional","affiliation":[{"name":"Program in Dermatopathology Brigham and Women's Hospital, Harvard Medical School  Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyun","family":"Xu","sequence":"additional","affiliation":[{"name":"Program in Dermatopathology Brigham and Women's Hospital, Harvard Medical School  Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander H.","family":"Frank","sequence":"additional","affiliation":[{"name":"Program in Dermatopathology Brigham and Women's Hospital, Harvard Medical School  Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Martin C.","family":"Mihm","sequence":"additional","affiliation":[{"name":"Department of Dermatology Brigham and Women's Hospital, Harvard Medical School  Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn P.M.","family":"Saw","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia  North Sydney Australia"},{"name":"Sydney Medical School The University of Sydney  Sydney NSW Australia"},{"name":"Discipline of Surgery Royal Prince Alfred Hospital  Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher D.","family":"Fletcher","sequence":"additional","affiliation":[{"name":"Department of Pathology Brigham and Women's Hospital, Harvard Medical School  Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Scolyer","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia  North Sydney Australia"},{"name":"Sydney Medical School The University of Sydney  Sydney NSW Australia"},{"name":"Tissue Pathology and Diagnostic Oncology Royal Prince Alfred Hospital  Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George F.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Program in Dermatopathology Brigham and Women's Hospital, Harvard Medical School  Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine G.","family":"Lian","sequence":"additional","affiliation":[{"name":"Program in Dermatopathology Brigham and Women's Hospital, Harvard Medical School  Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,2,6]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2014.87"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.07.033"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.224"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.5858\/2009-0612-RAR.1"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12564"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2014.99"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/81.24.1893"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200401000-00002"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6062"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1502583"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.12.019"},{"issue":"10","key":"e_1_2_5_13_1","first-page":"994","article-title":"The genetic evolution of melanoma","volume":"374","author":"Lian CG","year":"2016","journal-title":"N Engl J Med"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181b94f3c"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181cf7fa0"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.5858\/2010-0146-RA.1"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000198"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70608-9"}],"container-title":["Journal of Cutaneous Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcup.12880","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cup.12880","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T18:11:58Z","timestamp":1696356718000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cup.12880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,6]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1111\/cup.12880"],"URL":"https:\/\/doi.org\/10.1111\/cup.12880","archive":["Portico"],"relation":{},"ISSN":["0303-6987","1600-0560"],"issn-type":[{"value":"0303-6987","type":"print"},{"value":"1600-0560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,6]]}}}